Incidence of clinical complications according to lymphocyte
recovery
The 180-days CI of CMV infection was significantly higher for patients
with ALC and CD3+CD8+ recovered on D+100 (Table 2). Higher infection
rates were also observed in females (57% vs. male 29%,P =0.004), advanced malignancy (56% vs. early 26%,P =0.03), haplo-HSCT (58% vs. MSD 33%, unrelated donor 30%,P =0.02) and with PBSC vs. BM (64% vs. 36%, P =0.01). In
the multivariate analysis, ALC<500/µL and
CD3+CD8+<200/µL effects on CMV infection remained significant
(Table 3).
The 1-year CI of aGvHD ≥grade 2 was higher in haplo-HSCT (24% vs.
unrelated donor 9%, MSD 7%, P =0.006), with PBSC (43% vs. BM
9%, P =0.003) and malignant diseases (17% vs. non-malignant 9%,P =0.02). Inadequate CD3+CD4+ recovery was the only immune
parameter associated with aGvHD (Table 2). In univariate analysis, this
recovery represented a lower risk for the disease occurrence with a
Hazard ratio (HR) of 0.23 (0.07-0.76, P =0.02). Multivariate
analysis revealed that CD3+CD4+ recovery remained significant when
adjusted for the use of PBSC and haplo-HSCT (Table 3).